Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Medical Device Bootcamp

Related Content

US Senate Probes FDA Bureaucracy vs. Innovation

Stronger Together: NORD’s Congressional Briefing on the Heels of FDA’s “Plausible Mechanism” Draft Guidance

FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN

New Oral Polio Vaccine Type 2 (nOPV2) Prequalified by WHO

Formycon and Lotus Expand Collaboration in Asia-Pacific Region to Pembrolizumab Biosimilar

Shareholder Activism in Life Sciences: Risks, Responses, and Outlook

Samsung and Regeneron Settle Aflibercept BPCIA Case

Express Scripts Settles PBM FTC Action and Must Make Fundamental Changes to PBM Model

Goodwin Guides Candel Therapeutics on $100 Million Public Offering and $100 Millon Royalty Funding Agreement With RTW

Goodwin Advises Nektar Therapeutics on its $460 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Goodwin Guides Gannet BioChem on Acquisition of Laysan Bio

Goodwin Advises Bruder Consulting & Venture Group on its Acquisition by Dark Horse Consulting Group

Goodwin Achieves Record Number of Rankings in Chambers Global 2026

The Future of Life Sciences Antitrust

Goodwin Advises Agomab on Pricing of $200 Million Initial Public Offering

Goodwin Advises Orna Therapeutics in Acquisition by Eli Lilly for Up to $2.4 Billion

Life Sciences

Technology